Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors

NCT00336765 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT00336765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2006
Completion date
September 30, 2010
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer